Advertisement
"Exercise of this option by GSK caps a productive first few months duringwhich Amira has hit a number of near term milestones. Hitting thesemilestones early has not only further strengthened our relations with GSK, buthas resulted in meaningful economic benefit to Amira," said Hari Kumar, ChiefBusiness Officer, Amira. "The project has started extremely well and we arevery pleased at the commitment of GSK and the progression of development."
Advertisement
About FLAP Inhibitors
FLAP (5-Lipoxygenase Activating Protein) is a key component early in theleukotriene pathway, a complex signaling process that exerts control overbiological processes, such as inflammation and immunity. Excessive productionof leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAPgene has also been linked to a significant increase in the risk of myocardialinfarction and stroke. AM103 and AM803 bind to FLAP, inhibiting the synthesisof leukotrienes that cause inflammation.
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is asmall molecule pharmaceutical company focused on the discovery and earlydevelopment of compounds to treat inflammatory disease linked to theeicosanoid pathway.
The company combines the rigor of a big pharmaceutical company with theingenuity and energy of a small company, creating an environment for efficientand effective pre-clinical and clinical program decisions. Its scientificfounders have successfully worked together for more than a decade and werepivotal in the discovery of a number of inflammatory drugs, includingSingulair(R). The drug hunters at Amira are now actively leveraging theirhistory of success to create high-value compounds for the future. For moreinformation, visit http://www.amirapharm.com.
SOURCE Amira Pharmaceuticals
